Skip to main content
Premium Trial:

Request an Annual Quote

Scipher Medicine Raises $82M in Series C Financing

NEW YORK – Scipher Medicine said today that it has completed an $82 million Series C financing led by aMoon and Northpond Ventures, with participation from Echo Health Ventures and existing investors, Khosla Ventures and Alumni Ventures.

Adding the new Series C to prior fundraising, the company said it has raised $117 million in total.

Scipher plans to use the proceeds to expand commercial efforts for its PrismRA test, which employs an RNA-based molecular signature to identify individuals with rheumatoid arthritis who are unlikely to adequately respond to TNFi therapy and should consider alternative, more effective therapies.

The financing will also support research collaborations to identify novel treatment targets using the firm's growing clinico-genomic database.

"With more data being generated from tested patients every day, we are continuously serving our provider, payer, and pharma partnerships with unique insights into the most optimal treatment pathway for patients with autoimmune diseases," Scipher CEO Alif Saleh said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.